Liquid Biopsy Test for Breast Cancer Developed by Reveal Genomics Shows Excellent Results in Clinical Study

According to the World Health Organization, breast cancer is the most common cancer among women worldwide. The earlier it is detected, the more chances of survival a patient has. Hence, the development of a non-invasive and accurate diagnostic tool for breast cancer is crucial for early detection and treatment. Recently, Reveal Genomics has developed a Liquid Biopsy Test for breast cancer detection that has shown remarkable results in clinical studies.

What is a Liquid Biopsy Test?

A Liquid Biopsy Test is a non-invasive diagnostic test that detects the presence of cancer cells in a patient’s blood sample instead of an invasive biopsy procedure. It is also called a blood test for cancer, and it is a more convenient and less painful alternative to traditional biopsy procedures. The Liquid Biopsy Test has been used to detect multiple types of cancer, including lung, colorectal, and breast cancer.

Reveal Genomics Develops a Liquid Biopsy Test for Breast Cancer

Reveal Genomics have developed a Liquid Biopsy Test that targets a specific breast cancer cell type that spreads cancer cells and is resistant to chemotherapy. The Liquid Biopsy Test analyzes the DNA and RNA present in a patient’s blood sample and looks for genetic mutations that indicate the presence of cancer cells. The Liquid Biopsy Test developed by Reveal Genomics has shown promising results in clinical studies conducted on multiple breast cancer patients.

Promising Results from Clinical Studies

The Liquid Biopsy Test developed by Reveal Genomics has shown an 84% accuracy rate in detecting breast cancer in patients. The clinical studies have also shown that the Liquid Biopsy Test can detect metastasized or advanced stage breast cancer in patients, which is generally difficult to detect with traditional biopsy procedures. Reveal Genomics is also working on improving the accuracy rate of their Liquid Biopsy Test to make it a more reliable diagnostic tool for breast cancer.

Conclusion

Breast cancer is a severe health concern worldwide, and early detection is crucial for a patient’s survival. Reveal Genomics has developed a Liquid Biopsy Test for breast cancer that has shown promising results in clinical studies. The Liquid Biopsy Test is a non-invasive and less painful alternative to traditional biopsy procedures, making it easier for patients to undergo the diagnostic process. This test can detect metastasized or advanced stage breast cancer, which is challenging to detect with traditional biopsy procedures. The accuracy rate of the Liquid Biopsy Test is expected to improve as the company continues to research and develop the diagnostic tool.

#BreastCancerDetection #LiquidBiopsyTest #NonInvasiveDiagnosticTool #EarlyDetection #RevealGenomics

Summary: Reveal Genomics has developed a liquid biopsy test for detecting breast cancer, which is a non-invasive, more convenient, and less painful alternative to traditional biopsy procedures. Clinical studies have shown a promising 84% accuracy rate in detecting breast cancer in patients. This test can detect metastasized or advanced stage breast cancer, which is generally difficult to detect with traditional biopsy procedures. #BUSINESS